Accumulation of murine amyloid-β mimics early Alzheimer's disease

被引:40
|
作者
Krohn, Markus [1 ,2 ,3 ]
Bracke, Alexander [4 ]
Avchalumov, Yosef [5 ]
Schumacher, Toni [3 ]
Hofrichter, Jacqueline [3 ]
Paarmann, Kristin [1 ,2 ,3 ]
Froehlich, Christina [3 ]
Lange, Cathleen [3 ]
Bruening, Thomas [1 ,2 ,3 ]
Halbach, Oliver von Bohlen Und
Pahnke, Jens [1 ,2 ,3 ,6 ,7 ]
机构
[1] Univ Oslo UiO, Dept Neuropathol, Translat Neurodegenerat Res & Neuropathol Lab, Oslo, Norway
[2] Oslo Univ Hosp OUS, Oslo, Norway
[3] Univ Rostock, Dept Neurol, D-18055 Rostock, Germany
[4] Ernst Moritz Arndt Univ Greifswald, Dept Anat, Greifswald, Germany
[5] Univ Rostock, Dept Physiol, D-18055 Rostock, Germany
[6] Univ Lubeck, LIED, Lubeck, Germany
[7] Leibniz Inst Plant Biochem, Dept Bioorgan Chem, Halle, Germany
关键词
ABCC1; neprilysin; ABCB1; Alzheimer's disease; MCI; amyloidosis; BLOOD-BRAIN-BARRIER; CENTRAL-NERVOUS-SYSTEM; MOUSE MODEL; P-GLYCOPROTEIN; PRECURSOR PROTEIN; IN-VIVO; A-BETA; NEUTRAL ENDOPEPTIDASE; SYNAPTIC PLASTICITY; PYRAMIDAL NEURONS;
D O I
10.1093/brain/awv137
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Almost all mouse models of Alzheimer's disease use expression of human transgenes to trigger amyloid pathology. Krohn <italic toggle="yes">et al. introduce a new mouse model without transgene expression that, in common with patients with sporadic Alzheimer's disease, shows reduced amyloid-beta clearance. The model shows pathology reminiscent of early-stage Alzheimer's disease.Almost all mouse models of Alzheimer's disease use expression of human transgenes to trigger amyloid pathology. Krohn <italic toggle="yes">et al. introduce a new mouse model without transgene expression that, in common with patients with sporadic Alzheimer's disease, shows reduced amyloid-beta clearance. The model shows pathology reminiscent of early-stage Alzheimer's disease.Amyloidosis mouse models of Alzheimer's disease are generally established by transgenic approaches leading to an overexpression of mutated human genes that are known to be involved in the generation of amyloid-beta in Alzheimer's families. Although these models made substantial contributions to the current knowledge about the 'amyloid hypothesis' of Alzheimer's disease, the overproduction of amyloid-beta peptides mimics only inherited (familiar) Alzheimer's disease, which accounts for < 1% of all patients with Alzheimer's disease. The inherited form is even regarded a 'rare' disease according to the regulations for funding of the European Union ( ext-link-type="uri" xlink:href="http://www.erare.eu">www.erare.eu). Here, we show that mice that are double-deficient for neprilysin (encoded by <italic toggle="yes">Mme), one major amyloid-beta-degrading enzyme, and the ABC transporter ABCC1, a major contributor to amyloid-beta clearance from the brain, develop various aspects of sporadic Alzheimer's disease mimicking the clinical stage of mild cognitive impairment. Using behavioural tests, electrophysiology and morphological analyses, we compared different ABC transporter-deficient animals and found that alterations are most prominent in neprilysin x ABCC1 double-deficient mice. We show that these mice have a reduced probability to survive, show increased anxiety in new environments, and have a reduced working memory performance. Furthermore, we detected morphological changes in the hippocampus and amygdala, e.g. astrogliosis and reduced numbers of synapses, leading to defective long-term potentiation in functional measurements. Compared to human, murine amyloid-beta is poorly aggregating, due to changes in three amino acids at N-terminal positions 5, 10, and 13. Interestingly, our findings account for the action of early occurring amyloid-beta species/aggregates, i.e. monomers and small amyloid-beta oligomers. Thus, neprilysin x ABCC1 double-deficient mice present a new model for early effects of amyloid-beta-related mild cognitive impairment that allows investigations without artificial overexpression of inherited Alzheimer's disease genes.
引用
收藏
页码:2370 / 2382
页数:13
相关论文
共 50 条
  • [21] Metabolism of amyloid-β peptide and Alzheimer's disease
    Iwata, N
    Higuchi, M
    Saido, TC
    PHARMACOLOGY & THERAPEUTICS, 2005, 108 (02) : 129 - 148
  • [22] Alzheimer's disease: the ins and outs of amyloid-β
    Beyreuther, Konrad
    Masters, Colin L.
    Nature, 1997, 389 (6652):
  • [23] Aluminum and Amyloid-β in Familial Alzheimer's Disease
    Mold, Matthew
    Linhart, Caroline
    Gomez-Ramirez, Johana
    Villegas-Lanau, Andres
    Exley, Christopher
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 73 (04) : 1627 - 1635
  • [24] Amyloid-β: A double agent in Alzheimer's disease?
    Yu, Hao
    Wu, Jie
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 139
  • [25] Citrullination of Amyloid-β Peptides in Alzheimer's Disease
    Mukherjee, Soumya
    Perez, Keyla A.
    Dubois, Celine
    Nisbet, Rebecca M.
    Li, Qiao-Xin
    Varghese, Shiji
    Jin, Liang
    Birchall, Ian
    Streltsov, Victor A.
    Vella, Laura J.
    McLean, Catriona
    Barham, Kevin J.
    Roberts, Blaine R.
    Masters, Colin L.
    ACS CHEMICAL NEUROSCIENCE, 2021, 12 (19): : 3719 - 3732
  • [26] Synaptic activity, amyloid-β and Alzheimer's disease
    Cirrito, John R.
    Holtzman, David M.
    ALZHEIMER: 100 YEARS AND BEYOND, 2006, : 209 - +
  • [27] Amyloid-β-directed immunotherapy for Alzheimer's disease
    Lannfelt, L.
    Relkin, N. R.
    Siemers, E. R.
    JOURNAL OF INTERNAL MEDICINE, 2014, 275 (03) : 284 - 295
  • [28] Amyloid-β and Glucose Metabolism in Alzheimer's Disease
    Furst, Ansgar J.
    Lal, Rayhan A.
    JOURNAL OF ALZHEIMERS DISEASE, 2011, 26 : 105 - 116
  • [29] Synaptic Retrogenesis and Amyloid-β in Alzheimer's Disease
    Wasling, Pontus
    Daborg, Jonny
    Riebe, Ilse
    Andersson, My
    Portelius, Erik
    Blennow, Kaj
    Hanse, Eric
    Zetterberg, Henrik
    JOURNAL OF ALZHEIMERS DISEASE, 2009, 16 (01) : 1 - 14
  • [30] Role of Mitochondrial Amyloid-β in Alzheimer's Disease
    Chen, John Xi
    Yan, Shirley Shidu
    JOURNAL OF ALZHEIMERS DISEASE, 2010, 20 : S569 - S578